Yahoo · Oct 21, 2026
Sector Update: Healthcare Stocks Decline Wednesday Afternoon
Healthcare stocks declined Wednesday afternoon, with the NYSE Healthcare Index down 0.7% and the Sta
IR
NASDAQ · IRD
Opus Genetics, Inc.
Healthcare · Biotechnology
$3.67
Up+$0.02 (+0.55%)
Updated Nov 2, 2026, 12:17 PM
SID Score
4.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 167.86M
- P/E ratio
- -2.65
- Dividend yield
- 0.00%
- 52-week range
- $1.70 – $7.07
- Volume
- 1.02M
- Avg. volume
- 528.52K
Price performance · IRD
IRD price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
IRD closed at $3.67 after 20 trading sessions, down 16.21% for the selected period.
- Last close
- $3.67
- Period change
- -16.21%
- Period low
- $3.32
- Period high
- $4.65
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $3.58 | $3.69 | $3.42 | $3.67 | 1.02M |
| Oct 29, 2026 | $3.68 | $3.82 | $3.60 | $3.65 | 709.6K |
| Oct 28, 2026 | $3.44 | $3.69 | $3.40 | $3.68 | 1.03M |
| Oct 27, 2026 | $3.32 | $3.53 | $3.28 | $3.46 | 1.3M |
| Oct 26, 2026 | $3.49 | $3.50 | $3.23 | $3.32 | 1.52M |
| Oct 23, 2026 | $3.79 | $3.83 | $3.44 | $3.47 | 1.12M |
| Oct 22, 2026 | $4.04 | $4.10 | $3.80 | $3.82 | 894.74K |
| Oct 21, 2026 | $4.03 | $4.215 | $4.00 | $4.115 | 1.36M |
| Oct 20, 2026 | $3.82 | $4.145 | $3.78 | $4.01 | 1.46M |
| Oct 19, 2026 | $3.87 | $3.9399 | $3.69 | $3.82 | 1.53M |
| Oct 16, 2026 | $4.12 | $4.13 | $3.75 | $3.84 | 2.53M |
| Oct 15, 2026 | $4.15 | $4.2799 | $3.975 | $4.05 | 2.95M |
| Oct 14, 2026 | $4.395 | $4.395 | $4.08 | $4.10 | 1.2M |
| Oct 13, 2026 | $4.76 | $4.77 | $4.23 | $4.24 | 1.3M |
| Oct 12, 2026 | $4.63 | $4.88 | $4.60 | $4.64 | 1.62M |
| Oct 9, 2026 | $4.46 | $4.74 | $4.45 | $4.65 | 1.26M |
| Oct 8, 2026 | $4.41 | $4.48 | $4.245 | $4.46 | 1.35M |
| Oct 7, 2026 | $4.35 | $4.66 | $4.25 | $4.41 | 1.84M |
| Oct 6, 2026 | $4.465 | $4.48 | $4.185 | $4.38 | 2.54M |
| Oct 5, 2026 | $4.57 | $4.64 | $4.34 | $4.38 | 2.54M |
Latest IRD news
The latest Smart Investors Daily articles mentioning IRD.
Stock researchCompany · Overview
Company
Market Activity
Research & News
IRD research
Overview
Company profile and research snapshot.
Company profile
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $7.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 22, 2026 | Chardan Capital | Buy | — |
| Oct 16, 2026 | Citizens | Market Outperform | — |
| Oct 6, 2026 | Jones Trading | Buy | — |
| Oct 2, 2026 | Chardan Capital | Buy | — |
| Sep 10, 2026 | Wedbush | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 21, 2026
Opus Genetics Announces FDA Clearance of IND Application for OPGx-RDH12 Gene Therapy for Inherited Childhood Blindness
FDA clearance enables clinical development of OPGx-RDH12 for RDH12-associated Leber congenital amaurosis, a rare inherited retinal disease that causes progressive vision loss beginning in early childhood Strategic collaboration with the Global RDH12 Alliance supports the development of a potential treatment for this disease with high unmet need RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage bi
Benzinga · Oct 21, 2026
FDA Clears Opus Genetics’ IND Application For Opgx-RDH12, Investigational Gene Therapy For Treatment Of RDH12-Associated Leber Congenital Amaurosis
FDA clearance enables clinical development of OPGx-RDH12 for RDH12-associated Leber congenital amaurosis, a rare inherited retinal disease that causes progressive vision loss beginning in early childhoodStrategic
Yahoo · Oct 16, 2026
Opus Genetics Secures FDA Approval For Eye Drops – Set To Receive Milestone Payment
The approval expands the therapy's use and triggers a milestone payment from commercial partner Viatris.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
